Search Results - "DOBRINSKA, M. R"

Refine Results
  1. 1

    Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin by Gruer, Peter J.K, Vega, Jose M, Mercuri, Michele F, Dobrinska, Michael R, Tobert, Jonathan A

    Published in The American journal of cardiology (01-10-1999)
    “…The long-term safety profile of simvastatin, established over 10 years of clinical use, is excellent. The principal adverse effect of all inhibitors of…”
    Get full text
    Journal Article
  2. 2

    The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day by Davidson, Michael H., Stein, Evan A., Dujovne, Carlos A., Hunninghake, Donald B., Weiss, Stuart R., Knopp, Robert H., Illingworth, D.Roger, Mitchel, Yale B., Melino, Michael R., Zupkis, Robert V., Dobrinska, Michael R., Amin, Raju D., Tobert, Jonathan A.

    Published in The American journal of cardiology (01-01-1997)
    “…The hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin is the most effective of the currently approved hypolipidemic drugs and has been shown to…”
    Get full text
    Journal Article
  3. 3

    Use of In Vitro Drug Metabolism Data to Evaluate Metabolic Drug-Drug Interactions in Man: The Need for Quantitative Databases by Rodrigues, A. David, Winchell, Gregory A., Dobrinska, Michael R.

    Published in Journal of clinical pharmacology (01-04-2001)
    “…It has become widely accepted that metabolic drug‐drug interactions can be forecast using in vitro cytochrome P450 (CYP) data. For any CYP form‐inhibitor pair,…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Fully automated methods for the determination of hydrochlorothiazide in human plasma and urine by Hsieh, J Y, Lin, C, Matuszewski, B K, Dobrinska, M R

    “…LC assays utilizing fully automated sample preparation procedures on Zymark PyTechnology Robot and BenchMate Workstation for the quantification of…”
    Get more information
    Journal Article
  6. 6
  7. 7

    Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin by HAIYUNG CHENG, ROGERS, J. D, SWEANY, A. E, DOBRINSKA, M. R, STEIN, E. A, TATE, A. C, AMIN, R. D, HUI QUAN

    Published in Pharmaceutical research (01-12-1992)
    “…The effects of age and of gender on the plasma profiles of HMG-CoA reductase inhibitors following separate once-a-day dosage regimens (17 days) of lovastatin…”
    Get full text
    Journal Article
  8. 8

    The Use of Stable Isotope Labeling and Liquid Chromatography/Tandem Mass Spectrometry Techniques to Study the Pharmacokinetics and Bioavailability of the Antimigraine Drug, MK-0462 (Rizatriptan) in Dogs by Barrish, A., Olah, T. V., Gatto, G. J., Dobrinska, M. R., Gilbert, J. D.

    “…MK‐0462 (rizatriptan) is a 5HT1D agonist being developed for the treatment of migraine. The assay for this substance in plasma and urine is based on HPLC with…”
    Get full text
    Journal Article
  9. 9

    An automated sample preparation and high performance liquid chromatographic method for the determination of MK-591, a novel leukotriene biosynthesis inhibitor, in human plasma by Lin, Charles, Hsieh, John Y.-K., Matuszewski, Bogdan K., Dobrinska, Michael R.

    “…A high performance liquid chromatography assay utilizing an automated sample preparation procedure for the determination of a novel leukotriene biosynthesis…”
    Get full text
    Journal Article
  10. 10

    Biotransformation of sulindac in end-stage renal disease by Gibson, T P, Dobrinska, M R, Lin, J H, Entwistle, L A, Davies, R O

    Published in Clinical pharmacology and therapeutics (01-07-1987)
    “…In normal humans sulindac, a prodrug, undergoes two major biotransformations: irreversible oxidation to the inactive sulfone metabolite and reversible…”
    Get more information
    Journal Article
  11. 11

    Bioavailability of fluvoxamine given with and without food by Van Harten, J, Van Bemmel, P, Dobrinska, M R, Ferguson, R K, Raghoebar, M

    Published in Biopharmaceutics & drug disposition (01-11-1991)
    “…The influence of concomitant food intake on plasma concentrations of the antidepressant drug fluvoxamine maleate was investigated in a two-way, crossover study…”
    Get more information
    Journal Article
  12. 12

    Stereoselectivity in the disposition and metabolism of the uricosuric-diuretic agent, indacrinone, in Rhesus monkeys by Zacchei, A G, Dobrinska, M R, Wishousky, T I, Kwan, K C, White, S D

    Published in Drug metabolism and disposition (01-01-1982)
    “…The physiological disposition following intravenous dosing of the separate enantiomers of indacrinone-14C (I), and of their major metabolite,…”
    Get more information
    Journal Article
  13. 13

    Sensitive high-performance liquid chromatographic assay using electrochemical detection for a novel prodrug ester of methyldopa, pivaloyloxyethyl 3-(3,4-dihydroxyphenyl)-2-methylalaninate, in plasma and urine by Musson, D G, Vincek, W C, Dobrinska, M R, Vickers, S, Leidy, H L

    Published in Journal of chromatography (08-06-1984)
    “…The pivaloyloxyethyl ester of methyldopa is an antihypertensive prodrug possessing improved bioavailability properties over methyldopa. A sensitive…”
    Get more information
    Journal Article
  14. 14

    In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration by LIN, Yvonne S, LOCKWOOD, Graham F, THUMMEL, Kenneth E, GRAHAM, Martin A, BRIAN, William R, LOI, Cho-Ming, DOBRINSKA, Michael R, SHEN, Danny D, WATKINS, Paul B, WILKINSON, Grant R, KHARASCH, Evan D

    Published in Pharmacogenetics (London) (01-12-2001)
    “…We investigated whether a single plasma midazolam concentration could serve as an accurate predictor of total midazolam clearance, an established in-vivo probe…”
    Get full text
    Journal Article
  15. 15

    Determination of felodipine, its enantiomers, and a pyridine metabolite in human plasma by capillary gas chromatography with mass spectrometric detection by Dru, J.D.-Y., Hsieh, J.Y.-K., Matuszewski, B.K., Dobrinska, M.R.

    “…Sensitive methods based on capillary gas chromatography (GC) with mass spectrometric (MS) detection in a selected-ion monitoring mode (SIM) for the…”
    Get full text
    Journal Article
  16. 16

    Biliary secretion of sulindac and metabolites in man by Dobrinska, M R, Furst, D E, Spiegel, T, Vincek, W C, Tompkins, R, Duggan, D E, Davies, R O, Paulus, H E

    Published in Biopharmaceutics & drug disposition (01-10-1983)
    “…The biliary secretion of sulindac and metabolites after a single 400 mg oral dose of the drug was studied in 3 elective gallbladder surgical patients following…”
    Get more information
    Journal Article
  17. 17

    Enterohepatic circulation of sulindac and metabolites by Dujovne, C A, Pitterman, A, Vincek, W C, Dobrinska, M R, Davies, R O, Duggan, D E

    Published in Clinical pharmacology and therapeutics (01-02-1983)
    “…Four subjects were studied by continuous intraduodenal sampling to establish the existence and determine the extent of enterohepatic recirculation of sulindac…”
    Get more information
    Journal Article
  18. 18

    Metabolism of methyldopa in man after oral administration of the pivaloyloxyethyl ester by Vickers, S, Duncan, C A, Ramjit, H G, Dobrinska, M R, Dollery, C T, Gomez, H J, Leidy, H L, Vincek, W C

    Published in Drug metabolism and disposition (01-03-1984)
    “…In a crossover study, the pivaloyloxyethyl ester (POE) of methyldopa, labeled either with 3H in the methyldopa moiety or 14C in the pivalic acid moiety, was…”
    Get more information
    Journal Article
  19. 19
  20. 20

    Pharmacokinetics of the pivaloyloxyethyl (POE) ester of methyldopa, a new prodrug of methyldopa by Dobrinska, M R, Kukovetz, W, Beubler, E, Leidy, H L, Gomez, H J, Demetriades, J, Bolognese, J A

    “…A prodrug of methyldopa, the pivaloyloxyethyl (POE) ester, was administered orally to healthy human volunteers at doses equivalent to 500 and 1000 mg of…”
    Get more information
    Journal Article